A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Hemophilia A Clinical Trial

Official title:

A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02571569
• Other study ID #: 16144
• Secondary ID: 2014-003283-20
• Status: Completed
• Phase: Phase 1
• Start date: October 28, 2015
• Est. completion date: October 11, 2018

Study information

• Verified date: October 2018
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of multiple doses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 11, 2018
• Est. primary completion date: July 9, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males with severe congenital Hemophilia A or B defined as <1% FVIII or Factor IX (FIX) concentration by measurement at the time of screening or from reliable prior documentation

• For subjects in Cohorts I-IV, I-SC1 and I-SC2; If history of inhibitors is evident, inhibitor titer of =5 Bethesda Units (BU) at screening or prior to screening at any time from medical records.

• Age: 18 to 65 years of age at screening

• Body mass index (BMI): 18 to 29.9 kg/m²

Exclusion Criteria:

• Subjects with known bleeding disorders (such as von Willebrand factor [vWF] deficiency, FXI deficiency, platelet disorders, or known acquired or inherited thrombophilia etc.) other than congenital Hemophilia A or B with or without inhibitors

• History of angina pectoris or treatment for angina pectoris

• History of coronary and/or peripheral atherosclerotic disease, congestive heart failure, disseminated intravascular coagulopathy, or stage 2 hypertension defined as systolic blood pressure (SBP) =160 mmHg or diastolic blood pressure (DBP) =100 mmHg even if controlled

• History of thrombophlebitis, venous / arterial thromboembolic diseases (particularly deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, cerebrovascular accident, ischemic heart disease, transient ischemic attack)

• Known or suspected hypersensitivity of the immune system, history of anaphylactic reaction, known (clinically relevant) allergies, non-allergic drug reactions, or multiple drug allergies

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia B

Intervention

Drug:
• BAY1093884
Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
• BAY1093884
Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Bulgaria,  Germany,  Japan,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants (single dose cohors) with adverse events as measure of safety and tolerability	Adverse events including abnormal laboratory findings and local injection site reactions	Up to 56 days
Primary	Plasma levels of anti-BAY1093884 antibodies		Pre-dose, Day 14, 21,28, 43 and 56
Primary	Plasma concentration of BAY1093884 characterized by AUC(0-tlast)	AUC from time 0 to the last data point > LLOQ (lower limit of quantitation)	Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion
Primary	Plasma concentration of BAY1093884 characterized by AUC(0-tlast)/D	AUC(0-last) divided by dose	Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion
Primary	Plasma concentration of BAY1093884 characterized by Cmax	Maximum observed drug concentration in measured matrix after single dose administration	Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion
Primary	Plasma concentration of BAY1093884 characterized by Cmax/D	Cmax divided by dose	Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion
Secondary	Tissue factor pathway inhibitor (TFPI) activity		Up to 77 days
Secondary	Number of participants (multiple dose cohort) with adverse events as a measure of safety and tolerability	Adverse events including abnormal laboratory findings and local injection site reactions	Up to 77 days
Secondary	Plasma levels of anti-BAY1093884 antibodies (multiple dose cohort)		Pre-dose, Day 14, 28, 49 and 77
Secondary	Plasma concentration of BAY1093884 characterized by AUC(0-7d and AUC(0-tau) (multiple dose cohort)	AUC from time 0 to 7d after first and last dose (AUC(0-tau)	Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42
Secondary	Plasma concentration of BAY1093884 characterized by AUC(0-7d/D and AUC(0-tau)/D after multiple dose	AUC(0-7d) after first dose and AUC(0-tau) after last dose divided by dose	Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42
Secondary	Plasma concentration of BAY1093884 characterized by Cmax after first dose and last dose (Cmax,md)	maximum observed drug concentration in measured matrix after first and last dose	Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42
Secondary	Plasma concentration of BAY1093884 characterized by Cmax/D after first dose and last dose (Cmax,md/D)	Cmax after first and last dose divided by dose	Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42
Secondary	Accumulation of BAY 1093884 in plasma as defined by ratio for Cmax and AUC (after first and last dose)	Cmax after last dose divided by Cmax after first dose, AUC after last dose divided by AUC after first dose	Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.